Fitzpatrick Institute for Photonics Fitzpatrick Institute for Photonics
Pratt School of Engineering
Duke University
 HOME > pratt > FIP    Search Help Login 

Gayathri R Devi, Associate Professor of Surgery

Contact Info:
Office Location:  401 Med.Sci.Res.Building
Office Phone:  (919) 668-0410
Email Address: send me a message
Web Page:  http://faculty.duhs.duke.edu/faculty/info?pid=13698

Education:

Ph.D.University of Nebraska College of Medicine1998

Representative Publications   (More Publications)

  1. JL Allensworth, SJ Sauer, HK Lyerly, MA Morse, GR Devi, Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism., Breast cancer research and treatment, vol. 137 no. 2 (January, 2013), pp. 359-71, ISSN 1573-7217 [doi]  [abs]
  2. JL Allensworth, KM Aird, AJ Aldrich, I Batinic-Haberle, GR Devi, XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells., Molecular cancer therapeutics, vol. 11 no. 7 (July, 2012), pp. 1518-27, ISSN 1538-8514 [doi]  [abs]
  3. V Piacentino 3rd, CA Milano, M Bolanos, J Schroder, E Messina, AS Cockrell, E Jones, A Krol, N Bursac, L Mao, GR Devi, RJ Samulski, DE Bowles, X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector., Human gene therapy, vol. 23 no. 6 (June, 2012), pp. 635-46, ISSN 1557-7422 [doi]  [abs]
  4. KM Aird, JL Allensworth, I Batinic-Haberle, HK Lyerly, MW Dewhirst, GR Devi, ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells., Breast cancer research and treatment, vol. 132 no. 1 (February, 2012), pp. 109-19, ISSN 1573-7217 [doi]  [abs]
  5. MA Morse, A Hobeika, D Serra, K Aird, M McKinney, A Aldrich, T Clay, D Mourich, HK Lyerly, PL Iversen, GR Devi, Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function., Cancer gene therapy, vol. 19 no. 1 (January, 2012), pp. 30-7, ISSN 1476-5500 [doi]  [abs]
  6. F Rangwala, KP Williams, GR Smith, Z Thomas, JL Allensworth, HK Lyerly, AM Diehl, MA Morse, GR Devi, Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines., BMC cancer, vol. 12 no. 1 (2012), pp. 402, ISSN 1471-2407 [doi]  [abs]
  7. ZI Thomas, W Gibson, JZ Sexton, KM Aird, SM Ingram, A Aldrich, HK Lyerly, GR Devi, KP Williams, Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration., British journal of cancer, vol. 104 no. 10 (May, 2011), pp. 1575-86, ISSN 1532-1827 [doi]  [abs]
  8. TM Clay, T Osada, ZC Hartman, A Hobeika, G Devi, MA Morse, HK Lyerly, Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines., Immunologic research, vol. 49 no. 1-3 (April, 2011), pp. 235-47, ISSN 1559-0755 [doi]  [abs]
  9. MA Morse, AC Hobeika, T Osada, P Berglund, B Hubby, S Negri, D Niedzwiecki, GR Devi, BK Burnett, TM Clay, J Smith, HK Lyerly, An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer., The Journal of clinical investigation (August, 2010), ISSN 1558-8238 [doi]  [abs]
  10. MA Morse, J Wei, Z Hartman, W Xia, XR Ren, G Lei, WT Barry, T Osada, AC Hobeika, S Peplinski, H Jiang, GR Devi, W Chen, N Spector, A Amalfitano, HK Lyerly, TM Clay, Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo., International journal of cancer. Journal international du cancer, vol. 126 no. 12 (June, 2010), pp. 2893-903, ISSN 1097-0215 [doi]  [abs]
  11. KM Aird, RB Ghanayem, S Peplinski, HK Lyerly, GR Devi, X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor., Molecular cancer therapeutics, vol. 9 no. 5 (May, 2010), pp. 1432-42, ISSN 1538-8514 [doi]  [abs]
  12. ZC Hartman, J Wei, T Osada, O Glass, G Lei, XY Yang, S Peplinski, DW Kim, W Xia, N Spector, J Marks, W Barry, A Hobeika, G Devi, A Amalfitano, MA Morse, HK Lyerly, TM Clay, An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity., Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 16 no. 5 (March, 2010), pp. 1466-77, ISSN 1078-0432 [doi]  [abs]
  13. T Osada, D Hsu, S Hammond, A Hobeika, G Devi, TM Clay, HK Lyerly, MA Morse, Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody., British journal of cancer, vol. 102 no. 1 (January, 2010), pp. 124-33, ISSN 1532-1827 [doi]  [abs]
  14. PL Iversen, KM Aird, R Wu, MM Morse, GR Devi, Cellular uptake of neutral phosphorodiamidate morpholino oligomers., Current pharmaceutical biotechnology, vol. 10 no. 6 (September, 2009), pp. 579-88, ISSN 1873-4316  [abs]
  15. X Ding, AB Mohd, Z Huang, T Baba, MQ Bernardini, HK Lyerly, A Berchuck, SK Murphy, AB Buermeyer, GR Devi, MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition., British journal of cancer, vol. 101 no. 2 (July, 2009), pp. 269-77, ISSN 1532-1827 [doi]  [abs]
  16. JC Mavropoulos, WC Buschemeyer 3rd, AK Tewari, D Rokhfeld, M Pollak, Y Zhao, PG Febbo, P Cohen, D Hwang, G Devi, W Demark-Wahnefried, EC Westman, BL Peterson, SV Pizzo, SJ Freedland, The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model., Cancer prevention research (Philadelphia, Pa.), vol. 2 no. 6 (June, 2009), pp. 557-65, ISSN 1940-6215 [doi]  [abs]
  17. GR Devi, Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells., Methods in molecular biology (Clifton, N.J.), vol. 542 (2009), pp. 351-61, ISSN 1064-3745 [doi]  [abs]
  18. HS Sekhon, CA London, M Sekhon, PL Iversen, GR Devi, c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model., Lung cancer (Amsterdam, Netherlands), vol. 60 no. 3 (June, 2008), pp. 347-54, ISSN 0169-5002 [doi]  [abs]
  19. KM Aird, X Ding, A Baras, J Wei, MA Morse, T Clay, HK Lyerly, GR Devi, Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression., Molecular cancer therapeutics, vol. 7 no. 1 (January, 2008), pp. 38-47, ISSN 1535-7163 [doi]  [abs]
  20. MA Morse, A Hobeika, T Osada, D Niedzwiecki, PK Marcom, KL Blackwell, C Anders, GR Devi, HK Lyerly, TM Clay, Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2., Journal of translational medicine, vol. 5 (2007), pp. 42, ISSN 1479-5876 [doi]  [abs]
  21. GR Devi, siRNA-based approaches in cancer therapy., Cancer gene therapy, vol. 13 no. 9 (September, 2006), pp. 819-29, ISSN 0929-1903 [doi]  [abs]
  22. GR Devi, TM Beer, CL Corless, V Arora, DL Weller, PL Iversen, In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors., Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 11 no. 10 (May, 2005), pp. 3930-8, ISSN 1078-0432 [doi]  [abs]
  23. V Arora, GR Devi, PL Iversen, Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics., Current pharmaceutical biotechnology, vol. 5 no. 5 (October, 2004), pp. 431-9, ISSN 1389-2010  [abs]
  24. YJ Ko, GR Devi, CA London, A Kayas, MT Reddy, PL Iversen, GJ Bubley, SP Balk, Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers., The Journal of urology, vol. 172 no. 3 (September, 2004), pp. 1140-4, ISSN 0022-5347 [doi]  [abs]
  25. A Amantana, CA London, PL Iversen, GR Devi, X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells., Molecular cancer therapeutics, vol. 3 no. 6 (June, 2004), pp. 699-707, ISSN 1535-7163  [abs]
  26. GR Devi, XIAP as target for therapeutic apoptosis in prostate cancer., Drug news & perspectives, vol. 17 no. 2 (March, 2004), pp. 127-34, ISSN 0214-0934  [abs]
  27. CA London, HS Sekhon, V Arora, DA Stein, PL Iversen, GR Devi, A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity., Cancer gene therapy, vol. 10 no. 11 (November, 2003), pp. 823-32, ISSN 0929-1903 [doi]  [abs]
  28. PL Iversen, V Arora, AJ Acker, DH Mason, GR Devi, Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans., Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 9 no. 7 (July, 2003), pp. 2510-9, ISSN 1078-0432  [abs]
  29. DC Knapp, JE Mata, MT Reddy, GR Devi, PL Iversen, Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model., Anti-cancer drugs, vol. 14 no. 1 (January, 2003), pp. 39-47, ISSN 0959-4973  [abs]
  30. GR Devi, JR Oldenkamp, CA London, PL Iversen, Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells., The Prostate, vol. 53 no. 3 (November, 2002), pp. 200-10, ISSN 0270-4137 [doi]  [abs]
  31. GR Devi, CC Sprenger, SR Plymate, RG Rosenfeld, Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo., The Prostate, vol. 51 no. 2 (May, 2002), pp. 141-52, ISSN 0270-4137 [doi]  [abs]
  32. GR Devi, Prostate cancer: status of current treatments and emerging antisense-based therapies., Current opinion in molecular therapeutics, vol. 4 no. 2 (April, 2002), pp. 138-48, ISSN 1464-8431  [abs]
  33. GR Devi, DL Graham, Y Oh, RG Rosenfeld, Effect of IGFBP-3 on IGF- and IGF-analogue-induced insulin-like growth factor-I receptor (IGFIR) signalling., Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, vol. 11 no. 4 (August, 2001), pp. 231-9, ISSN 1096-6374 [doi]  [abs]
  34. GR Devi, DH Yang, RG Rosenfeld, Y Oh, Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling., Endocrinology, vol. 141 no. 11 (November, 2000), pp. 4171-9, ISSN 0013-7227  [abs]
  35. A López-Bermejo, CK Buckway, GR Devi, V Hwa, SR Plymate, Y Oh, RG Rosenfeld, Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium., Endocrinology, vol. 141 no. 11 (November, 2000), pp. 4072-80, ISSN 0013-7227  [abs]
  36. RG Rosenfeld, V Hwa, L Wilson, A Lopez-Bermejo, C Buckway, C Burren, WK Choi, G Devi, A Ingermann, D Graham, G Minniti, A Spagnoli, Y Oh, The insulin-like growth factor binding protein superfamily: new perspectives., Pediatrics, vol. 104 no. 4 Pt 2 (October, 1999), pp. 1018-21, ISSN 0031-4005  [abs]
  37. GR Devi, AT De Souza, JC Byrd, RL Jirtle, RG MacDonald, Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers., Cancer research, vol. 59 no. 17 (September, 1999), pp. 4314-9, ISSN 0008-5472  [abs]
  38. JC Byrd, GR Devi, AT de Souza, RL Jirtle, RG MacDonald, Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations., The Journal of biological chemistry, vol. 274 no. 34 (August, 1999), pp. 24408-16, ISSN 0021-9258  [abs]
  39. GR Devi, JC Byrd, DH Slentz, RG MacDonald, An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor., Molecular endocrinology (Baltimore, Md.), vol. 12 no. 11 (November, 1998), pp. 1661-72, ISSN 0888-8809  [abs]
  40. F Garmroudi, G Devi, DH Slentz, BS Schaffer, RG MacDonald, Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding., Molecular endocrinology (Baltimore, Md.), vol. 10 no. 6 (June, 1996), pp. 642-51, ISSN 0888-8809  [abs]

Duke University * Pratt * Reload * Login
x